Chapter 12. Target-Directed Drug Discovery

  1. Sotiris Missailidis
  1. Tracey D. Bradshaw

Published Online: 7 NOV 2008

DOI: 10.1002/9780470697047.ch12

Anticancer Therapeutics

Anticancer Therapeutics

How to Cite

Bradshaw, T. D. (2008) Target-Directed Drug Discovery, in Anticancer Therapeutics (ed S. Missailidis), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9780470697047.ch12

Editor Information

  1. Department of Chemistry and Analytical Sciences, The Open University, Milton Keynes, UK

Author Information

  1. Centre for Biomolecular Sciences, School of Pharmacy, University of Nottingham, Nottingham, UK

Publication History

  1. Published Online: 7 NOV 2008
  2. Published Print: 21 NOV 2008

ISBN Information

Print ISBN: 9780470723036

Online ISBN: 9780470697047



  • target-directed drug discovery;
  • ‘caretaker’ genes and mutations;
  • non-small cell lung cancer (NSCLC) targeted therapy;
  • EGFR inhibitors - Iressa and Tarceva;
  • Gefinitib - EGFR inhibitor;
  • chronic myeloid leukaemia pathogenesis;
  • VEGFR signal transduction activation;
  • targeting cell cycling;
  • chemistry-driven drug discovery


This chapter contains sections titled:

  • Introduction

  • Tyrosine Kinases – Role and Significance in Cancer

  • Targeted Therapy for the Treatment of Non-small Cell Lung Cancer (NSCLC)

  • Targeted Therapy for the Treatment of Chronic Myeloid Leukaemia

  • Targeted Therapy for the Treatment of Breast Cancer

  • Angiogenesis

  • Targeting Cell Cycling

  • Targeting Apoptosis

  • Targeting mTOR

  • The Future of Molecularly Targeted Therapy

  • References